Interpace Biosciences Announces Collaborative Study with University of North Carolina to Assess the Use BarreGEN® after Ablation of Dysplastic Barrett’s Esophagus
06 janv. 2020 06h55 HE
|
Interpace Biosciences, Inc.
Parsippany, NJ, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG), a leader in enabling personalized medicine, today announced that the Company’s wholly-owned subsidiary,...
Interpace Biosciences Announces New Draft LCD and Reimbursement for Its Proprietary Thyroid Assay, ThyGeNEXT®
17 déc. 2019 06h55 HE
|
Interpace Biosciences, Inc.
Parsippany, NJ, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced that its Medicare Administrative Contractor (MAC) has issued a new draft local coverage...
Interpace Biosciences Expands Strategic Partnership Activities with Genecast Biotechnology in China
05 déc. 2019 06h55 HE
|
Interpace Biosciences, Inc.
Further Strengthens Business Development Team with Key Hire PARSIPPANY, N.J., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Interpace Bioscience’s subsidiary, Interpace Pharma Solutions today announced...
Interpace Diagnostics Changes Name to Interpace Biosciences; Announces Plans for Next Phase of Growth and Third Quarter 2019 Financial Results
13 nov. 2019 16h40 HE
|
Interpace Biosciences, Inc.
Third Quarter Revenue Grew 34% Over the Prior Year’s Quarter and 25% Year to Date Acquired BioPharma Business in Partnership with Ampersand Diagnostic Test Volume Grew 16% for the Quarter and...